Search

Your search keyword '"J. Videčnik-Zorman"' showing total 4 results
Start Over Author "J. Videčnik-Zorman" Topic hepacivirus
4 results on '"J. Videčnik-Zorman"'

1. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

Author

Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, Gheorghe L, El Hassan ES, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alashgar HI, Alawadhi S, Al-Dabal L, Aldins P, Alfaleh FZ, Alghamdi AS, Al-Hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Alzaabi M, Andrea N, Assiri AM, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Blach S, Chaudhry A, Choi MS, Diab T, Djauzi S, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor Khan A, Goldis A, Gottfredsson M, Gregorcic S, Hajarizadeh B, Han KH, Hasan I, Hashim A, Horvath G, Hunyady B, Husni R, Jafri W, Jeruma A, Jonasson JG, Karlsdottir B, Kim DY, Kim YS, Koutoubi Z, Lesmana LA, Lim YS, Löve A, Maimets M, Makara M, Malekzadeh R, Matičič M, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Nugrahini N, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Salupere R, Sanai FM, Sanityoso Sulaiman A, Sayegh RA, Schmelzer JD, Sibley A, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tarifi H, Tayyab G, Tolmane I, Ud Din M, Umar M, Valantinas J, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, and Gunter J

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents therapeutic use, Child, Child, Preschool, Female, Genotype, Global Health, Hepacivirus classification, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic therapy, Humans, Infant, Infant, Newborn, Liver Transplantation, Male, Middle Aged, Prevalence, Young Adult, Hepacivirus isolation & purification, Hepatitis C, Chronic epidemiology, Hepatitis C, Chronic virology
Abstract

Detailed, country-specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates were gathered from the literature and validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Iran and Lebanon to 4.2% in Pakistan. The largest viraemic populations were in Pakistan (7 001 000 cases) and Indonesia (3 187 000 cases). Injection drug use (IDU) and a historically unsafe blood supply were major risk factors in most countries. Diagnosis, treatment and liver transplant rates varied widely between countries. However, comparison across countries was difficult as the number of cases changes over time. Access to reliable data on measures such as these is critical for the development of future strategies to manage the disease burden., (© 2015 John Wiley & Sons Ltd.)

Published
2015
Full Text
View/download PDF

2. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

Author

Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, Salupere R, Assiri AM, Goldis A, Abaalkhail F, Abbas Z, Abdou A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alavian SM, Alashgar HI, Alawadhi S, Al-Dabal L, Aldins P, Alfaleh FZ, Alghamdi AS, Al-Hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Alzaabi M, Andrea N, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Blach S, Chaudhry A, Choi MS, Diab T, Djauzi S, El Hassan ES, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor Khan A, Gheorghe L, Gottfredsson M, Gregorcic S, Gunter J, Hajarizadeh B, Hamid S, Hasan I, Hashim A, Horvath G, Hunyady B, Husni R, Jeruma A, Jonasson JG, Karlsdottir B, Kim DY, Kim YS, Koutoubi Z, Liakina V, Lim YS, Löve A, Maimets M, Malekzadeh R, Matičič M, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Nugrahini N, Olafsson S, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Sanai FM, Sanityoso Sulaiman A, Sayegh RA, Sharara AI, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tanaka J, Tarifi H, Tayyab G, Tolmane I, Ud Din M, Umar M, Valantinas J, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, and Schmelzer JD

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Cost of Illness, Female, Global Health, Hepatitis C, Chronic mortality, Hepatitis C, Chronic therapy, Humans, Incidence, Male, Middle Aged, Prevalence, Survival Analysis, Viremia mortality, Viremia therapy, Young Adult, Hepacivirus isolation & purification, Hepatitis C, Chronic epidemiology, Hepatitis C, Chronic virology, Models, Statistical, Viremia epidemiology, Viremia virology
Abstract

The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV) infections change over time making it difficult to compare reported estimates from different years. Models were developed for 15 countries to quantify and characterize the viraemic population and forecast the changes in the infected population and the corresponding disease burden from 2014 to 2030. With the exception of Iceland, Iran, Latvia and Pakistan, the total number of viraemic HCV infections is expected to decline from 2014 to 2030, but the associated morbidity and mortality are expected to increase in all countries except for Japan and South Korea. In the latter two countries, mortality due to an ageing population will drive down prevalence, morbidity and mortality. On the other hand, both countries have already experienced a rapid increase in HCV-related mortality and morbidity. HCV-related morbidity and mortality are projected to increase between 2014 and 2030 in all other countries as result of an ageing HCV-infected population. Thus, although the total number of HCV countries is expected to decline in most countries studied, the associated disease burden is expected to increase. The current treatment paradigm is inadequate if large reductions in HCV-related morbidity and mortality are to be achieved., (© 2015 John Wiley & Sons Ltd.)

Published
2015
Full Text
View/download PDF

3. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Author

V. Liakina, S. Hamid, J. Tanaka, S. Olafsson, A. I. Sharara, S. M. Alavian, L. Gheorghe, E. S. El Hassan, F. Abaalkhail, Z. Abbas, A. Abdou, A. Abourached, F. Al Braiki, F. Al Hosani, K. Al Jaberi, M. Al Khatry, M. A. Al Mulla, H. Al Quraishi, A. Al Rifai, Y. Al Serkal, A. Alam, H. I. Alashgar, S. Alawadhi, L. Al-Dabal, P. Aldins, F. Z. Alfaleh, A. S. Alghamdi, R. Al-Hakeem, A. A. Aljumah, A. Almessabi, A. N. Alqutub, K. A. Alswat, I. Altraif, M. Alzaabi, N. Andrea, A. M. Assiri, M. A. Babatin, A. Baqir, M. T. Barakat, O. M. Bergmann, A. R. Bizri, S. Blach, A. Chaudhry, M. S. Choi, T. Diab, S. Djauzi, S. El Khoury, C. Estes, S. Fakhry, J. I. Farooqi, H. Fridjonsdottir, R. A. Gani, A. Ghafoor Khan, A. Goldis, M. Gottfredsson, S. Gregorcic, B. Hajarizadeh, K. H. Han, I. Hasan, A. Hashim, G. Horvath, B. Hunyady, R. Husni, W. Jafri, A. Jeruma, J.G. Jonasson, B. Karlsdottir, D. Y. Kim, Y. S. Kim, Z. Koutoubi, L. A. Lesmana, Y. S. Lim, A. Löve, M. Maimets, M. Makara, R. Malekzadeh, M. Matičič, M. S. Memon, S. Merat, J. E. Mokhbat, F. H. Mourad, D. H. Muljono, A. Nawaz, N. Nugrahini, S. Priohutomo, H. Qureshi, P. Rassam, H. Razavi, D. Razavi-Shearer, K. Razavi-Shearer, B. Rozentale, M. Sadik, K. Saeed, A. Salamat, R. Salupere, F. M. Sanai, A. Sanityoso Sulaiman, R. A. Sayegh, J. D. Schmelzer, A. Sibley, M. Siddiq, A. M. Siddiqui, G. Sigmundsdottir, B. Sigurdardottir, D. Speiciene, A. Sulaiman, M. A. Sultan, M. Taha, H. Tarifi, G. Tayyab, I. Tolmane, M. Ud din, M. Umar, J. Valantinas, J. Videčnik-Zorman, C. Yaghi, E. Yunihastuti, M. A. Yusuf, B. F. Zuberi, and J. Gunter

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Genotype, Population, Hepacivirus, Global Health, Antiviral Agents, Young Adult, Virology, Environmental health, Epidemiology, Prevalence, Global health, Humans, Medicine, Infection control, Child, education, Disease burden, Aged, Aged, 80 and over, education.field_of_study, Hepatology, business.industry, Public health, Infant, Newborn, Infant, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Liver Transplantation, Infectious Diseases, Child, Preschool, Immunology, Female, business, Viral hepatitis
Abstract

Detailed, country‐specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates were gathered from the literature and validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Iran and Lebanon to 4.2% in Pakistan. The largest viraemic populations were in Pakistan (7001000 cases) and Indonesia (3187000 cases). Injection drug use (IDU) and a historically unsafe blood supply were major risk factors in most countries. Diagnosis, treatment and liver transplant rates varied widely between countries. However, comparison across countries was difficult as the number of cases changes over time. Access to reliable data on measures such as these is critical for the development of future strategies to manage the disease burden.

Published
2015

4. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3

Author

A. Sibley, K. H. Han, A. Abourached, L. A. Lesmana, M. Makara, W. Jafri, R. Salupere, A. M. Assiri, A. Goldis, F. Abaalkhail, Z. Abbas, A. Abdou, F. Al Braiki, F. Al Hosani, K. Al Jaberi, M. Al Khatry, M. A. Al Mulla, H. Al Quraishi, A. Al Rifai, Y. Al Serkal, A. Alam, S. M. Alavian, H. I. Alashgar, S. Alawadhi, L. Al-Dabal, P. Aldins, F. Z. Alfaleh, A. S. Alghamdi, R. Al-Hakeem, A. A. Aljumah, A. Almessabi, A. N. Alqutub, K. A. Alswat, I. Altraif, M. Alzaabi, N. Andrea, M. A. Babatin, A. Baqir, M. T. Barakat, O. M. Bergmann, A. R. Bizri, S. Blach, A. Chaudhry, M. S. Choi, T. Diab, S. Djauzi, E. S. El Hassan, S. El Khoury, C. Estes, S. Fakhry, J. I. Farooqi, H. Fridjonsdottir, R. A. Gani, A. Ghafoor Khan, L. Gheorghe, M. Gottfredsson, S. Gregorcic, J. Gunter, B. Hajarizadeh, S. Hamid, I. Hasan, A. Hashim, G. Horvath, B. Hunyady, R. Husni, A. Jeruma, J. G. Jonasson, B. Karlsdottir, D. Y. Kim, Y. S. Kim, Z. Koutoubi, V. Liakina, Y. S. Lim, A. Löve, M. Maimets, R. Malekzadeh, M. Matičič, M. S. Memon, S. Merat, J. E. Mokhbat, F. H. Mourad, D. H. Muljono, A. Nawaz, N. Nugrahini, S. Olafsson, S. Priohutomo, H. Qureshi, P. Rassam, H. Razavi, D. Razavi-Shearer, K. Razavi-Shearer, B. Rozentale, M. Sadik, K. Saeed, A. Salamat, F. M. Sanai, A. Sanityoso Sulaiman, R. A. Sayegh, A. I. Sharara, M. Siddiq, A. M. Siddiqui, G. Sigmundsdottir, B. Sigurdardottir, D. Speiciene, A. Sulaiman, M. A. Sultan, M. Taha, J. Tanaka, H. Tarifi, G. Tayyab, I. Tolmane, M. Ud din, M. Umar, J. Valantinas, J. Videčnik-Zorman, C. Yaghi, E. Yunihastuti, M. A. Yusuf, B. F. Zuberi, and J. D. Schmelzer

Subjects
Adult, Aged, 80 and over, Male, Models, Statistical, Hepatology, Adolescent, Incidence, Hepacivirus, Hepatitis C, Chronic, Middle Aged, Global Health, Survival Analysis, Young Adult, Infectious Diseases, Cost of Illness, Virology, Prevalence, Humans, Female, Viremia, Aged
Abstract

The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV) infections change over time making it difficult to compare reported estimates from different years. Models were developed for 15 countries to quantify and characterize the viraemic population and forecast the changes in the infected population and the corresponding disease burden from 2014 to 2030. With the exception of Iceland, Iran, Latvia and Pakistan, the total number of viraemic HCV infections is expected to decline from 2014 to 2030, but the associated morbidity and mortality are expected to increase in all countries except for Japan and South Korea. In the latter two countries, mortality due to an ageing population will drive down prevalence, morbidity and mortality. On the other hand, both countries have already experienced a rapid increase in HCV‐related mortality and morbidity. HCV‐related morbidity and mortality are projected to increase between 2014 and 2030 in all other countries as result of an ageing HCV‐infected population. Thus, although the total number of HCV countries is expected to decline in most countries studied, the associated disease burden is expected to increase. The current treatment paradigm is inadequate if large reductions in HCV‐related morbidity and mortality are to be achieved.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results